Literature DB >> 28778748

The clinical value of inflammatory biomarkers in coronary artery disease: PTX3 as a new inflammatory marker.

Tangmeng Guo1, Lili Huang2, Cunfei Liu3, Shengshuai Shan1, Qing Li4, Li Ke5, Bei Cheng6.   

Abstract

OBJECTIVE: Previous experiments have demonstrated that several inflammatory biomarkers, including pentraxin 3 (PTX3), matrix metalloprotein 9 (MMP9), interleukin-6 (IL-6), and the neutrophil to lymphocyte ratio (NLR), are differentially elevated in coronary artery disease (CAD). This study aims to compare the associations between plasma levels of these biomarkers and CAD, identifying the best biomarker that has the most powerful association with CAD.
METHODS: Blood samples were collected from 64 patients admitted to the Department of Cardiology, 31 of whom had CAD and 33 of whom were CAD-free. Plasma levels of PTX3, MMP9, and IL-6 were measured via ELISA. The coronary Gensini score was used to evaluate the severity of coronary artery lesions.
RESULTS: PTX3 levels and NLR levels between the CAD group and the CAD-free group were statistically significant (P<0.05). Stepwise multiple linear regression analysis showed that PTX3 levels and NLR levels were independently associated with CAD (r=1.3, P<0.05; r=1.8, P<0.05). Only PTX3 was associated with the severity of coronary artery stenosis. A PTX3 threshold of 4.38ng/mL maximized true-positive and false-negative results. PTX3 displayed a greater area under the receiver operating characteristic curve (AUC) than NLR, MMP9, and IL-6 (0.733 versus 0.612 versus 0.725 versus 0.518).
CONCLUSIONS: Compared to NLR, MMP9, and IL-6, PTX3 displayed greater AUC and association with CAD. PTX3 may become a potentially powerful inflammatory biomarker for CAD.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coronary artery disease; IL-6; Inflammatory biomarker; MMP9; NLR; PTX3

Mesh:

Substances:

Year:  2017        PMID: 28778748     DOI: 10.1016/j.exger.2017.07.018

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  7 in total

1.  Early expression of PTX3 in Aspergillus fumigatus infected rat cornea.

Authors:  Jie Zhang; Gui-Qiu Zhao; Jing Qu; Jing Lin; Cheng-Ye Che; Xue-Jiao Yang
Journal:  Int J Ophthalmol       Date:  2018-07-18       Impact factor: 1.779

2.  Pre-Clinical Tests of an Integrated CMOS Biomolecular Sensor for Cardiac Diseases Diagnosis.

Authors:  Jen-Kuang Lee; I-Shun Wang; Chi-Hsien Huang; Yih-Fan Chen; Nien-Tsu Huang; Chih-Ting Lin
Journal:  Sensors (Basel)       Date:  2017-11-26       Impact factor: 3.576

3.  SH3RF3 promotes breast cancer stem-like properties via JNK activation and PTX3 upregulation.

Authors:  Peiyuan Zhang; Yingjie Liu; Cheng Lian; Xuan Cao; Yuan Wang; Xiaoxun Li; Min Cong; Pu Tian; Xue Zhang; Gang Wei; Tong Liu; Guohong Hu
Journal:  Nat Commun       Date:  2020-05-19       Impact factor: 14.919

4.  Neutrophil Lymphocyte Ratio and Cardiovascular Disease Risk: A Systematic Review and Meta-Analysis.

Authors:  Teeranan Angkananard; Thunyarat Anothaisintawee; Mark McEvoy; John Attia; Ammarin Thakkinstian
Journal:  Biomed Res Int       Date:  2018-11-11       Impact factor: 3.411

Review 5.  Sudden Cardiac Death (SCD) - risk stratification and prediction with molecular biomarkers.

Authors:  Junaida Osman; Shing Cheng Tan; Pey Yee Lee; Teck Yew Low; Rahman Jamal
Journal:  J Biomed Sci       Date:  2019-05-22       Impact factor: 12.771

6.  Neutrophil to lymphocyte ratio is not related to carotid atherosclerosis progression and cardiovascular events in the primary prevention of cardiovascular disease: Results from the IMPROVE study.

Authors:  Massimo R Mannarino; Vanessa Bianconi; Bruna Gigante; Rona J Strawbridge; Kai Savonen; Sudhir Kurl; Philippe Giral; Andries Smit; Per Eriksson; Elena Tremoli; Fabrizio Veglia; Damiano Baldassarre; Matteo Pirro
Journal:  Biofactors       Date:  2021-11-11       Impact factor: 6.438

7.  Empagliflozin Inhibits IL-1β-Mediated Inflammatory Response in Human Proximal Tubular Cells.

Authors:  Markus Pirklbauer; Sebastian Sallaberger; Petra Staudinger; Ulrike Corazza; Johannes Leierer; Gert Mayer; Herbert Schramek
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.